Releasing this as price sensitive is frankly embarrassing. This is a totally standard dose ranging study that is done before every mouse study of a drug and takes a couple of weeks. These sort of mouse studies cost between $5 and $10k when outsourced to a CRO (contract research organisation). It is just slightly above announcing you dissolved your drug in a saline solution.
Assuming BIT have a new candidate drug for HBV, they will need to spend between $5 and $7 million and around 2 year to get any such candidate to be ready to dose a human (i.e. the CMC and non-clinical animal studies). I will leave it to others to decide if raising this sort of capital is likely for BIT. The muted response from the market suggests nobody does.
BIT Price at posting:
0.2¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)